Reliability and Interpretability of Sonographic Measurements of Palmar Dupuytren Nodules

Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial

“…At 12 months, by means of a quantitative assay, 48 (80%) of 60 of the participants randomly assigned and treated with adalimumab had antibodies to adalimumab higher than the threshold for detection, with a median (IQR) concentration of 29•8 ng/mL (2•4 to 128•8; appendix p 26). There no relationship between the concentration of circulating antibodies to adalimumab and change in durometer readings or nodule area, feret, or height at 12 months compared with baseline (appendix pp [27][28][29].…”

“…A systematic review 28 concluded that ultrasound scans would be useful for following the course of early-stage disease, a finding subsequently validated in a cohort of 50 patients. 29 An operator masked to the treatment allocation did all the ultrasound scans in the UK and also did all of the measurements. Reliability of sequential imaging was improved by ensuring that the images were recorded with the same deep landmarks, including the bones and joints, on each occasion.…”